Medicare Coverage Determination for Molecular Testing Announced for Solid Organ Allograft Rejection, Citing Multiple Publications from OncoCyte Corporation's Subsidiary Chronix Biomedical, Inc.

Stock Information for Oncocyte Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oncocyte Corporation

Oncocyte Reports Full Year 2023 Financial Results
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays
Oncocyte Reports Third Quarter 2023 Financial Results
Oncocyte to Announce Third Quarter 2023 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.